Efficacy and Safety of Ionized Atelocollagen Adhesion Barrier (Collabarrier®) in Spine Surgery
NCT ID: NCT07153822
Last Updated: 2025-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
69 participants
INTERVENTIONAL
2022-12-15
2024-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A total of 69 adult patients scheduled for first-time partial laminectomy or discectomy were enrolled and randomly assigned to receive either Collabarrier® or Guardix-sol. The investigational device (Collabarrier®) is a gel-type atelocollagen formulation designed to prevent postoperative adhesions by acting as a physical barrier between the dura mater and surrounding tissues.
The primary outcome was the mean MRI Scar Score at 6 weeks postoperatively, assessed by independent evaluators blinded to treatment allocation. Secondary outcomes included patient-reported pain scores using a 100-mm Visual Analog Scale (VAS) for low back and leg pain, and functional limitation assessed using the Oswestry Disability Index (ODI), measured at baseline, 3 weeks, and 6 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)
NCT04688281
Clinical Study to Evaluate the Anti-adhesion Efficacy and Safety of MegaShield®-SP in Comparison With Guardix-SP Plus After Spine Surgery
NCT06369233
A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation
NCT01283438
DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery
NCT00387829
Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)
NCT00637312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Collabarrier®
Collagen-based adhesion barrier
Porcine Atelocollagen (Type I)
Guardix-sol
Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier
Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collagen-based adhesion barrier
Porcine Atelocollagen (Type I)
Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier
Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with lumbar disc herniation or lumbar spinal stenosis based on radiological evidence (MRI or CT) showing nerve root compression at one of the following single levels: L3-L4, L4-L5, or L5-S1
* Patients scheduled to undergo their first partial laminectomy or discectomy for the above condition
* Patients who meet at least one of the following criteria (A, B, C):
* A. Have undergone a minimum of 4 weeks of prior conservative treatment within the 6 months prior to Visit 1 (e.g., physical therapy, use of anti-inflammatory drugs, or muscle relaxants)
* B. Experience intolerable pain and are judged by the investigator to require surgery for lumbar disc herniation or spinal stenosis
* C. Have significant progression of neurological functional loss
* Patients who voluntarily provide written informed consent and are able to comply with the study procedures and visit schedule
Exclusion Criteria
* Patients with a medical history of brittle bone
* Patients with a medical history of fracture in lumbar region or ligament injuries by external injury
* Patients who needs to undergo a spine surgery (osteotomy allowable) in addition to partial laminectomy or percutaneous lumbar discectomy for cure of symptom
* Patients with neurological function disorder on intestine/bladder
* Patients with any of such symptoms as excessive exudation, bleeding, acute edema and infection on the part applied
* Patients with Degenerative spinal disorder (other than disc herniation or spinal stenosis) or scoliosis (Cobb's angle is 15° or bigger)
* Patients with any of lymphatic disease, coagulation disoder and/or coagulant taken
* Patients with uncontrolled diabetes that may affect the surgery or the progress after surgery based on the tester's judgment
* Patients with desmosis or autoimmune disease or who has ever taken malignant tumor treatment within 5 years before this surgery
* Patients who has ever undergone a spine surgery on the part for this surgery
* Patients who has ever taken extradural steroid treatment within 2 weeks before surgery or oral steroid drug within 10 days before surgery
* Patients who has ever taken myelogram or lumbar puncture within 24 hours before screening
* Patients with impaired immunity or clinically significant abnormalities in clinical laboratory tests at screening Patients with immunity deteriorated or who shows clinically significant abnormality in lab test items at the moment of screening
* Patients who present clinically severe impairment in cardiovascular, digestive, respiratory, endocrine, or central nervous system, or have a mental illness that significantly affects the trial
* Participated in other clinical trials within 30 days from the screening
* A pregnant woman or lactating woman
* Patients who cannot comply with any requirement of the document form consent for this clinical test from the signing date of signature on the consent till the final day of visit
* Patients determined by the researcher to be non-conformable to this clinical trials.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DALIM TISSEN Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ajou University Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Seoul, , South Korea
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, , South Korea
The Catholic University of Korea St. Vincent's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRT-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.